Clinical trials: Nab-paclitaxel
Pancreatic Cancer, Pancreatic Carcinoma Non-resectable
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Unfortunately, despite the best clinical efforts and breakthroughs in biotechnology, most patients diagnosed with pancreatic cancer continue to die from the rapid progression of their disease.
- Conditions
- Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, Locally Advanced Malignant Neoplasm
- Trial name
- PILLAR (NCT01836432)
- Testing
- FOLFIRINOX, Algenpantucel-L Immunotherapy, 5-FU Chemoradiation
- Where
- 32 sites in United States
- Volunteers
- 302 people
- Sponsor
- NewLink Genetics Corporation
Mesothelioma, Pancreatic Cancer
A 2-part Phase 1/2 Open-label Trial on ODM-212
An open-label, multi-site, multi-cohort phase 1/2 trial to be conducted in 2 parts (dose escalation and dose expansion/optimisation)
- Conditions
- Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer)
- Trial name
- TEADCO (NCT07563738)
- Testing
- ODM-212, Ipilimumab and nivolumab, Gemcitabine and nab-paclitaxel
- Where
- 23 sites in United States, Denmark and 5 more
- Volunteers
- 229 people
- Sponsor
- Orion Corporation, Orion Pharma
Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer
A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC
This research study is studying an investigational drug, NC318, as a possible treatment for subjects with advanced or metastatic non-small cell lung cancer in combination with chemotherapy
- Trial name
- NCT04430933
- Testing
- NC318, Pemetrexed/Carboplatin, Nab paclitaxel/Carboplatin
- Sponsor
- NextCure, Inc.
Triple-Negative Breast Cancer
Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer
The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of magrolimab in combination with nab-paclitaxel or paclitaxel (cohort 1) or with sacituzumab govitecan-hziy (cohort 2) in…
- Trial name
- ELEVATE TNBC (NCT04958785)
- Testing
- Magrolimab, Nab-Paclitaxel, Paclitaxel
- Where
- 45 sites in United States, Australia and 4 more
- Volunteers
- 92 people
- Sponsor
- Gilead Sciences
Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy.
- Trial name
- NCT05635708
- Testing
- Tislelizumab, BGB-A445, LBL-007
- Where
- 61 sites in United States, Australia and 13 more
- Volunteers
- 418 people
- Sponsor
- BeiGene
Pancreatic Neoplasms
Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer
The purpose of this study is to determine the safety and efficacy of nab-paclitaxel combined with gemcitabine in Chinese patients with metastatic pancreatic cancer.
- Trial name
- PANC-001 (NCT02017015)
- Testing
- nab-paclitaxel, Gemcitabine
- Where
- 15 sites in China
- Volunteers
- 83 people
- Sponsor
- Celgene
Melanoma, Prostate Cancer
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
This is a first-in-human, open-label, dose escalation study to evaluate the safety and tolerability of pegilodecakin in participants with advanced solid tumors, dosed daily subcutaneously as a monotherapy or in combination with…
- Conditions
- Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma
- Trial name
- IVY (NCT02009449)
- Testing
- Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)
- Where
- 10 sites in United States
- Volunteers
- 353 people
- Sponsor
- Eli Lilly and Company
TNBC - Triple-Negative Breast Cancer, Ovarian Cancer
A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
This is a Phase 1/1b, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of etrumadenant (AB928) in combination with…
- Trial name
- NCT03719326
- Testing
- Etrumadenant, IPI-549, Pegylated liposomal doxorubicin (PLD)
- Where
- 27 sites in United States, Australia
- Volunteers
- 35 people
- Sponsor
- Arcus Biosciences, Inc.
Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
This study aimed to evaluate the safety and effectiveness of ociperlimab combined with tislelizumab and chemotherapy, compared to tislelizumab and chemotherapy alone, in participants with non-small cell lung cancer (NSCLC) that…
- Conditions
- Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV
- Trial name
- NCT05014815
- Testing
- Ociperlimab, Tislelizumab, Carboplatin
- Where
- 64 sites in United States, Australia and 6 more
- Volunteers
- 272 people
- Sponsor
- BeiGene
Angina Pectoris, Coronary Artery Disease
A Safety Study of ABI-007 for In-Stent Restenosis
This trial will treat patients with a new chemotherapeutic medicine who have undergone a successful and uncomplicated de novo stent placement in up to two native coronary arteries.
- Trial name
- NCT00093223
- Testing
- Paclitaxel Nanoparticle Albumin Bound
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Celgene
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
- Trial name
- NCT06607185
- Testing
- LY4066434., Cetuximab, Nab paclitaxel
- Where
- 45 sites in United States, Belgium and 6 more
- Volunteers
- 750 people
- Sponsor
- Eli Lilly and Company
Squamous Non-small Cell Lung Cancer
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Researchers want to know if intismeran autogene (the study treatment) given with pembrolizumab and chemotherapy can treat metastatic treatment-naive squamous non-small cell lung cancer (NSCLC).
- Trial name
- INTerpath-13 (NCT07221474)
- Testing
- Intismeran Autogene, Pembrolizumab, Carboplatin
- Where
- 55 sites in United States, Argentina and 9 more
- Volunteers
- 180 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor, TNBC - Triple-Negative Breast Cancer
PhI to Solid Tumors and PhII to Locally Advanced or mTNBC
PhI Dose Escalation with BOIN design in advanced Solid Tumor with Triple combination therapy to determine MTD and RP2D
- Trial name
- NCT05390710
- Testing
- LAE005 + Afuresertib + Nab-Paclitaxel
- Where
- 5 sites in China
- Volunteers
- 21 people
- Sponsor
- Laekna Limited
Triple Negative Breast Neoplasms
Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)
The purpose of this study is to evaluate the safety, tolerability and clinical activity of pembrolizumab (MK-3475) in combination with six chemotherapy regimens as neoadjuvant treatment for participants with triple negative…
- Trial name
- NCT02622074
- Testing
- Pembrolizumab, Nab-paclitaxel, Anthracycline (doxorubicin)
- Volunteers
- 60 people
- Sponsor
- Merck Sharp & Dohme LLC
Pancreatic Cancer
LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
The purpose of this study is to see if LOAd703 (an oncolytic adenovirus) can be safely given to patients with pancreatic cancer.
- Trial name
- NCT02705196
- Testing
- delolimogene mupadenorepvec, gemcitabine, nab-paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Lokon Pharma AB
Locally Advanced Breast Cancer, Triple Negative Breast Cancer
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeutic agents in the first- and…
- Conditions
- Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
- Trial name
- NCT06449222
- Testing
- BNT327 Dose Level 1 (DL1), BNT327 Dose Level 1 (DL2), Nab-placlitaxel
- Where
- 31 sites in United States, Australia and 2 more
- Volunteers
- 83 people
- Sponsor
- BioNTech SE
Pancreatic Adenocarcinoma Metastatic
Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma
This is a Phase 1b dose escalation trial of OMTX705, an anti-fibroblast activation protein (FAP) antibody-drug conjugate (ADC), in combination with gemcitabine/nab-paclitaxel and tislelizumab in patients with advanced/metastatic…
- Trial name
- NCT07377045
- Testing
- OMTX705, Nab-paclitaxel + Gemcitabine, Tislelizumab (i.v. 200mg)
- Where
- 7 sites in United States, Spain
- Volunteers
- 69 people
- Sponsor
- Oncomatryx Biopharma S.L.
Carcinoma, Non-Squamous Non-Small Cell Lung
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This randomized Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin+nab-paclitaxel…
- Trial name
- IMpower130 (NCT02367781)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Carboplatin, Nab-Paclitaxel
- Where
- 132 sites in United States, Belgium and 6 more
- Volunteers
- 723 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer
This study is a randomized, double-blind Phase 3 study to compare the efficacy and safety of Sindilizumab combined with chemotherapy or placebo combined with chemotherapy for neoadjuvant and adjuvant therapy for Resectable Stage…
- Trial name
- NCT05116462
- Testing
- Pemetrexed, Carboplatin, Paclitaxel
- Where
- China
- Volunteers
- 506 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Pancreatic Cancer
Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies
Phase 1 Safety and Tolerability Study in Subjects with Pancreatic Cancer or Other CA19-9 Positive Malignancies.
- Trial name
- NCT02672917
- Testing
- MVT-5873, modified FOLFIRINOX (mFOLFIRINOX), gemcitabine + nab-paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 118 people
- Sponsor
- BioNTech Research & Development, Inc.